Protara Therapeutics, Inc. (TARA) Stock

Protara Therapeutics, Inc. (TARA) is a Healthcare stock trading at $3.98 (as of 2026-06-18), with a market capitalization of $261.35M and a trailing P/E of -2.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing investigational therapies for cancer and rare diseases. Its lead program includes TARA-002, a cell therapy for lymphatic malformations, and it is also developing intravenous choline chloride for intestinal failure–associated liver disease.

Valuation — source: SEC EDGAR (first-party)
Price	$3.98
Market Cap	$261.35M
P/E Ratio	-2.9
EV / EBITDA	-3.0
Price / Book	1.22
Price / Sales	34.08
DCF Value (model)	$-16.84
DCF Upside vs Price	-523.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$6.38M
Net Margin	-900.3%
Return on Equity	-34.9%
Current Ratio	15.69
Revenue Growth (YoY)	53.0%
EPS Growth (YoY)	-38.2%
FCF Growth (YoY)	57.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	7.72 (safe)

Valuation vs Sector & Industry
Stock P/E	-2.9
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-113.9%
vs Industry	-117.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	JANUS HENDERSON GROUP PLC ($27.15M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jesse Shefferman
Employees	28
Country	US
IPO Date	2014-10-22

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.